Axsome Therapeutics: All Eyes On Auvelity Launch

Shares of Axsome Therapeutics have posted a 30% gain so far in 2022. Read more to understand why this stock needs to be watched.

Related Keywords

New York ,United States ,Blackrock ,Mark Coleman ,Roger Jeffs ,Mark Saad ,Eli Lilly ,Mark Jacobson ,Nick Pizzie ,Glaxosmithkline ,Amgen ,Ladenburg Thalmann ,Jazz Pharmaceuticals ,Corporate Development At Stemline Therapeutics ,Business Development Lori Englebert ,Pfizer ,Supernus Pharmaceuticals ,Health Sciences ,Therapist Meeting ,Axsome Therapeutics ,Core Biotech ,Wall Street ,Corporate Slides ,Breakthrough Therapy Designation ,European Sunosi ,Complete Response Letter ,Aerial Biopharma ,Sunosi Investor Event ,Adage Capital Partners ,Funds Management ,Chief Financial Officer Nick Pizzie ,Pierre Fabre United ,Chief Operating Officer Mark Jacobson ,Director Corporate Development ,Relmada Therapeutic ,Compass Pathways ,